GLPwatch
One small STEP, one giant leap: Semaglutide in the obese phenotype of heart failure with preserved ejection fraction.
Med · 2024
Last updated 2026-05-28In a trial of 529 obese patients with heart failure and preserved ejection fraction (HFpEF), those given semaglutide lost an average of 10.7% of their body weight over 52 weeks, compared to 1.8% in the placebo group. Semaglutide also improved heart failure-related symptoms and physical limitations.
AI summary of the abstract below.
| Journal | Med, 2024 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.23 |
| NIH percentile | 15 |
| Molecules | semaglutide |
| Conditions studied | Obesity, Heart Failure |
Abstract
While bodyweight reduction should be a primary intervention target in obese heart failure with preserved ejection fraction (HFpEF) patients, no pharmacological treatments have shown evidence. The STEP HFpEF trial showed that semaglutide significantly improved various aspects of heart failure-related clinical outcomes in obese HFpEF patients, along with remarkable weight loss.
Verbatim abstract via PubMed 38460497 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.